Rallybio (RLYB) Expected to Announce Earnings on Thursday

Rallybio (NASDAQ:RLYB) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Rallybio to post earnings of ($1.04) per share and revenue of $0.10 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 12:30 PM ET.

Rallybio Price Performance

Shares of RLYB stock opened at $10.77 on Tuesday. The company has a market cap of $56.87 million, a price-to-earnings ratio of -4.21 and a beta of -1.13. Rallybio has a 1 year low of $1.76 and a 1 year high of $11.49. The firm has a fifty day moving average price of $5.96 and a 200-day moving average price of $5.33.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $40.00.

Hedge Funds Weigh In On Rallybio

Hedge funds have recently modified their holdings of the company. Citadel Advisors LLC increased its stake in shares of Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the period. XTX Topco Ltd boosted its holdings in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares during the period. Finally, Geode Capital Management LLC increased its stake in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares in the last quarter. 90.34% of the stock is currently owned by institutional investors.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.